Population Analysis of Pharmacogenetic Polymorphisms Related to Acute Lymphoblastic Leukemia Drug Treatment | Zendy

Marcela A. Chiabai | Zendy; Tulio Cesar de Lima Lins | Zendy; Robert Pogue | Zendy; Rinaldo Wellerson Pereira | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Population Analysis of Pharmacogenetic Polymorphisms Related to Acute Lymphoblastic Leukemia Drug Treatment

Author(s) -

Marcela A. Chiabai,

Tulio Cesar de Lima Lins,

Robert Pogue,

Rinaldo Wellerson Pereira

Publication year - 2012

Publication title -

disease markers

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.912

H-Index - 66

eISSN - 1875-8630

pISSN - 0278-0240

DOI - 10.1155/2012/928940

Subject(s) - international hapmap project , pharmacogenetics , population , single nucleotide polymorphism , genotype , biology , genetics , ancestry informative marker , snp , medicine , gene , environmental health

This study aimed to evaluate in the Brazilian population, the genotypes and population frequencies of pharmacogenetic polymorphisms involved in the response to drugs used in treatment of acute lymphoblastic leukemia (ALL), and to compare the data with data from the HapMap populations. There was significant differentiation between most population pairs, but few associations between genetic ancestry and SNPs in the Brazilian population were observed. AMOVA analysis comparing the Brazilian population to all other populations retrieved from HapMap pointed to a genetic proximity with the European population. These associations point to preclusion of the use of genetic ancestry as a proxy for predicting drug response. In this way, any study aiming to correlate genotype with drug response in the Brazilian population should be based on pharmacogenetic SNP genotypes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research